Back to Report Store Home

PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets

  • Published: Jul-2018
  • Report Code: GBI090CBR
  • Report Format: pdf

Description

List of Figures

Figure 1: PI3K Marketed and Pipeline Landscape, Global, PI3K Signaling Network, 2018 8

Figure 2: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the PI3K/AKT/mTOR Pathway, 2018 16

Figure 3: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the PI3K/AKT/mTOR Pathway by Molecule Type, 2018 17

Figure 4: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the PI3K/AKT/mTOR Pathway by Therapy Area, 2018 18

Figure 5: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the Ras/Raf/MER/ERK Pathway, 2018 19

Figure 6: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the Ras/Raf/MER/ERK Pathway by Molecule Type, 2018 19

Figure 7: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for the Ras/Raf/MER/ERK Pathway by Therapy Area, 2018 20

Figure 8: PI3K Marketed and Pipeline Landscape, Gloal, Marketed Activity for Cell Survival Pathways Downstream of AKT, 2018 21

Figure 9: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Cell Survival Pathways Downstream of AKT by Molecule Type, 2018 21

Figure 10: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Cell Survival Pathways Downstream of AKT by Therapy Area, 2018 22

Figure 11: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Cell Cycle Progression Pathways Downstream of AKT, 2018 23

Figure 12: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Cell Cycle Progression Pathways Downstream of AKT by Molecule Type, 2018 24

Figure 13: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Cell Cycle Progression Pathways Downstream of AKT by Therapy Area, 2018 24

Figure 14: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Kinases Downstream of PDK1, 2018 25

Figure 15: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Kinases Downstream of PDK1 by Molecule Type, 2018 25

Figure 16: PI3K Marketed and Pipeline Landscape, Global, Marketed Activity for Kinases Downstream of PDK1 by Therapy Area, 2018 26

Figure 17: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Herceptin ($bn), 2006–2024 27

Figure 18: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Avastin ($bn), 2006–2024 28

Figure 19: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Lantus (insulin glargine) ($bn), 2006–2024 29

Figure 20: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Eylea (aflibercept) ($bn), 2011–2024 30

Figure 21: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Ibrance (palbociclib) ($bn), 2015–2024 31

Figure 22: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Novolog ($bn), 2006–2024 32

Figure 23: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Humalog ($bn), 2006–2024 33

Figure 24: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Perjeta ($bn), 2012–2024 34

Figure 25: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Avonex ($bn), 2006–2024 35

Figure 26: PI3K Marketed and Pipeline Landscape, Global, Historical and Forecast Annual Revenues for Levemir (insulin detemir) ($bn), 2006–2023 36

Figure 27: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the PI3K/AKT/mTOR Pathway, 2018 45

Figure 28: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the PI3K/AKT/mTOR Pathway by Novelty, 2018 47

Figure 29: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the PI3K/AKT/mTOR Pathway by Stage of Development, 2018 48

Figure 30: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the PI3K/AKT/mTOR Pathway by Molecule Type, 2018 49

Figure 31: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the PI3K/AKT/mTOR Pathway by Therapy Area, 2018 50

Figure 32: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Ras/Raf/MEK/ERK Pathway, 2018 50

Figure 33: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Ras/Raf/MEK/ERK Pathway by Novelty, 2018 51

Figure 34: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Ras/Raf/MEK/ERK Pathway by Stage of Development, 2018 51

Figure 35: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Ras/Raf/MEK/ERK Pathway by Molecule Type, 2018 52

Figure 36: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Ras/Raf/MEK/ERK Pathway by Therapy Area, 2018 53

Figure 37: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Cell Survival Pathways Downstream of AKT, 2018 54

Figure 38: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Cell Survival Pathways Downstream of AKT by Novelty, 2018 55

Figure 39: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Cell Survival Pathways Downstream of AKT by Stage of Development, 2018 56

Figure 40: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Cell Survival Pathways Downstream of AKT by Molecule Type, 2018 57

Figure 41: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for the Cell Survival Pathways Downstream of AKT by Therapy Area, 2018 58

Figure 42: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Cell-Cycle Progression Pathways Downstream of AKT, 2018 59

Figure 43: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Cell-Cycle Progression Pathways Downstream of AKT by Novelty, 2018 59

Figure 44: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Cell-Cycle Progression Pathways Downstream of AKT by Stage of Development, 2018 60

Figure 45: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Cell-Cycle Progression Pathways Downstream of AKT by Molecule Type, 2018 61

Figure 46: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Cell-Cycle Progression Pathways Downstream of AKT by Therapy Area, 2018 62

Figure 47: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Metabolism Pathways Downstream of AKT, 2018 63

Figure 48: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity Metabolism Pathways Downstream of AKT by Novelty, 2018 63

Figure 49: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Metabolism Pathways Downstream of AKT by Stage of Development, 2018 64

Figure 50: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Metabolism Pathways Downstream of AKT by Molecule Type, 2018 65

Figure 51: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Metabolism Pathways Downstream of AKT by Therapy Area, 2018 66

Figure 52: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Kinases Downstream of PDK1, 2018 66

Figure 53: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Kinases Downstream of PDK1 by Novelty, 2018 67

Figure 54: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Kinases Downstream of PDK1 by Stage of Development, 2018 67

Figure 55: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Kinases Downstream of PDK1 by Molecule Type, 2018 68

Figure 56: PI3K Marketed and Pipeline Landscape, Global, Pipeline Activity for Kinases Downstream of PDK1 by Therapy Area, 2018 69

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$2995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$5990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$8985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards